STEP 1 Trial Summary: What Semaglutide Actually Showed
STEP 1 is the trial that moved semaglutide from an interesting drug to a cultural event. In adults with overweight or obesity, mean weight change at 68 weeks was -14.9% with semaglutide 2.4 mg versus -2.4% with placebo, both alongside lifestyle intervention.[1]
That was genuinely important. But STEP 1 is often misread as proof that obesity medicine has been solved. It has not. The trial proved strong efficacy in a selected population under trial conditions. It did not abolish relapse, side effects, cost or the need for maintenance planning.[1][2]
The study enrolled adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, and compared once-weekly semaglutide 2.4 mg plus lifestyle intervention with placebo plus lifestyle intervention over 68 weeks.[1] This was a foundational efficacy trial. Its job was to answer whether semaglutide produced clinically meaningful weight loss. It did.
A far greater proportion of participants on semaglutide achieved thresholds such as 5%, 10% and 15% weight reduction, which matters because these are the ranges where blood pressure, glycaemic control, fatty liver and mechanical symptoms often begin to move in practice.[1] The side-effect profile was led mainly by gastrointestinal adverse events, which is unsurprising rather than disqualifying.[1][2]
What most articles miss is that STEP 1 was not a maintenance trial. It tells you what can be achieved over 68 weeks on treatment; it does not tell you what happens after stopping. That question sits more clearly in STEP 4 and off-treatment extension data.[3] The population also excluded some of the clinical untidiness seen in practice. Real-world care includes more comorbidity, more medication burden and more inconsistent adherence. Lifestyle support existed in both arms, so the results do not mean lifestyle is irrelevant; they mean lifestyle alone did not produce the same result.[1]
STEP 1 gives clinicians and patients a legitimate evidence base for serious pharmacological treatment of obesity. It supports semaglutide as more than a modest adjunct. But it also implies a higher standard of follow-up. The bigger the effect, the less sensible it is to treat the medication as a casual consumer purchase.
When to involve your clinician: early if nausea, vomiting or reduced intake are compromising hydration, exercise or other medication tolerance; if you are losing weight but not preserving strength; or if the drug is being started alongside complex antihypertensive or diabetes therapy.[2]
When to seek urgent help: severe abdominal pain, persistent vomiting, dehydration, possible gallbladder symptoms or suspected pancreatitis.[2]
Bottom line: STEP 1 deserved the attention it received. Semaglutide produced weight loss at a level previous drug therapy rarely approached. But the trial’s real value lies in giving obesity treatment medical seriousness, not in licensing complacency.[1][2]
FAQs
-
Average weight change at 68 weeks was -14.9% with semaglutide and -2.4% with placebo.[1]
-
No. STEP 1 focused on adults with overweight or obesity without diabetes.[1]
-
No. It proved efficacy during treatment. Questions about maintenance and withdrawal require later evidence such as STEP 4.[1][3]
-
Gastrointestinal side effects were the dominant adverse events, as with the wider GLP‑1 class.[1][2]
-
Because it set a new benchmark for obesity pharmacotherapy and changed what clinicians and patients consider possible.[1]
References
1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. https://jamanetwork.com/journals/jama/fullarticle/2777886
